# RNN 1st Gen Model Gilead Sciences, Inc. Biological products, except diagnostic
May 3, 2018
at 13-dec-2018
GILD
Model's trade recommendations 3.66% Return for period
5.37% Annual return
$87.20B Market Cap
β 1.19
GILD
Model (following trade recommendations)GILD
Underlying stockS&P 500
Index- 2.28 (3.41%) Div (Yield)
- BUY Analysts consensus recommendation
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Industry sector: Medical
Sector classification: Biological products, except diagnostic
Deep Learning based analysis and prediction model for Gilead Sciences, Inc. (GILD) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 23, 2015.
Market data for GILD model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 1287M |
| P/E | 8.67 |
| Shares Outstanding | 1304M |
| % Held by Insiders | 1.30% |
| % Held by Institutions | 78.43% |
| EPS (last reported FY) | $8.56 |
| EPS (last reported Q) | $1.37 |
| EPS, estimated (last reported Q) | $1.65 |
| Total revenues | $26 B |
| Net income | $5 B |